Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Articles
You have accessRestricted Access

Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials

Julián Segura, José A. García-Donaire and Luis M. Ruilope
JASN March 2005, 16 (3 suppl 1) S64-S66; DOI: https://doi.org/10.1681/ASN.2004110969
Julián Segura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José A. García-Donaire
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis M. Ruilope
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Abstract

Calcium channel blockers have been widely used in clinical practice because of their antihypertensive capacity. Prevention of renal damage is a very important aim of antihypertensive therapy. This is particularly so taking into account the high prevalence of chronic kidney disease (CKD) in the general population. Recent data have shown that CKD is related to the absence of adequate BP control and also to the clustering of other cardiovascular risk factors seen in the metabolic syndrome. The knowledge of the capacities of the different antihypertensive drugs or their combinations to simultaneously control BP while protecting the kidney and avoiding the facilitation of metabolic alterations is warranted. Recent data from the Intervention as a Goal in Hypertension Treatment trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and African American Study of Kidney Disease and Hypertension (AASK) allow the conclusion that in hypertensive patients with preserved renal function or with CKD, calcium channel blockers are effective antihypertensive drugs to be considered alone or in combination with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker.

Calcium channel blockers (CCB) are widely used for the treatment of cardiovascular disease, particularly angina pectoris, arrhythmias, and arterial hypertension. Their beneficial effects are related to systemic vasodilation caused by the inhibition of the inward flow of calcium ions through the L-type calcium channels in the cell membrane. Three main classes of CCB are in current use: The benzothiazepines (diltiazem), phenylalkylamines (verapamil), and dihydropiridines (nifedipine, amlodipine, and others).

A growing interest in the investigation of renal function in big trials that deal with different aspects of cardiovascular disease has developed in recent years. This is justified by different reasons, including the high prevalence of nephrosclerosis as a cause of ESRD (1) and the capacity of minor alterations of renal function to predict a poor outcome for the patients (2). The finding of a small increase in serum creatinine values, a diminished estimated GFR (<60 ml/min per 1.73 m2), microalbuminuria, and/or proteinuria heralds a significant elevation in cardiovascular events and death as well as in total mortality (2,3). These alterations are frequent in the hypertensive population and are related to an inadequate BP control and also to the clustering of other associated risk factors, particularly those seen in the metabolic syndrome (2–4).

The elevated prevalence of albuminuria and/or a diminished renal function in the general population in United States (5) and the frequent association of these alterations with high BP reinforces the need to know more about the long-term renal effects of the different antihypertensive agents or their combinations in the hypertensive population, in particular in patients who present with high BP and metabolic syndrome. This necessity is related to the potential capacity of these drugs to worsen the metabolic profile of the hypertensive patient, leading to an increase in the development of diabetes during the chronic administration of certain antihypertensive agents, thus facilitating further renal damage and cardiovascular risk (6).

CCB and Renal Protection in Recent Trials in Hypertensive Patients

Two recently published trials in which different antihypertensive agents were compared have shown that CCB could be particularly positive for the long-term maintenance of GFR levels when compared with a diuretic and with an angiotensin-converting enzyme (ACE) inhibitor. These were the Intervention as a Goal in Hypertension Treatment trial (INSIGHT) and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (7,8).

The INSIGHT study randomized 6321 hypertensive patients who had one or more associated risk factors to the dihydropyridine CCB, nifedipine gastrointestinal therapeutic system (GITS), or the diuretic combination hydrochlorothiazide/amilozide for the treatment of hypertension. BP control throughout the study was similar in both groups, with no statistically significant difference in the primary combined end point of cardiovascular death, nonfatal myocardial infarction, stroke, or heart failure. However, there was a small but significant decrease in estimated creatinine clearance during follow-up in the diuretic-treated patients compared with the one observed in those who received nifedipine GITS (7), suggesting that antihypertensive treatment that is based on a long-acting dihydropyridine may offer better renoprotection than therapy that is based on the diuretic combination co-amilozide.

The recent publication of the main results of the ALLHAT study also included the analysis of the changes observed in serum creatinine, slope of the reciprocal of serum creatinine, and also estimated creatinine clearance (8). The results show that a 448 of 33,357 patients developed ESRD without significant differences among the three arms of the study. The slopes of the reciprocal of serum creatinine over time were virtually identical in the chlorthalidone and lisinopril groups, whereas the decline in the amlodipine slope was significantly less than that of the chlorthalidone arm. Finally, the estimated creatinine clearance exhibited a significantly better preservation in the amlodipine arm that had a final mean value of 75.1 ml/min, than compared with 70.0 and 70.7 ml/min in the chlorthalidone and lisinopril groups, respectively.

These results seem to differ from the available evidence indicating that the administration of an ACE inhibitor or an angiotensin receptor blocker (ARB) is required to protect renal function beyond the benefit obtained by BP control (9). The better evolution observed in both the slope of the reciprocal of serum creatinine and the estimated creatinine clearance with a CCB argues against recently published comparative studies in which an ACE inhibitor or an ARB were shown to be better than a CCB in primary renal disease, in type 2 diabetic nephropathy, and in black patients with nephrosclerosis (10–12).

CCB, BP Control, and Renal Protection in the Presence of Preserved Renal Function

The capacity of a CCB to protect the kidney in hypertensive patients seems to depend mainly on the capacity of these drugs to lower BP as shown by the analysis of renal data in the Systolic Hypertension in Europe study (13), which demonstrated that lowering BP with nitrendipine caused a significant reduction in proteinuria and renal insufficiency events in patients who were actively treated with nitrendipine compared with those who took placebo (13).

The maintenance of a strict BP control represents the most relevant means to maintain a preserved renal function in hypertensive patients. In fact, a recent publication indicated that a very strict BP control attained a similar degree of renal protection in patients with type 2 diabetes, matching the control attained with enalapril or with the CCB nisoldipine (14). A good control of systemic BP counteracts the risk for afferent arteriolar vasodilation induced by the CCB by impeding the transmission of a still elevated systemic BP (15). A CCB then can be renoprotective in the presence of a preserved GFR provided that micro- or macroalbuminuria is not present. If albumin excretion is elevated, then an ACE inhibitor or an ARB is required to obtain full protection of the kidney (16,17).

The ALLHAT study demonstrated a very good control of BP with final mean values for systolic/diastolic BP of 133.9/75.4, 134.7/74.6, and 135.9/75.4 mmHg for chlorthalidone, amlodipine, and lisinopril, respectively, and with 66% of patients achieving BP values <140/90 mmHg (8). Small but significant differences in the control of systolic BP were seen in favor of the chlorthalidone arm, which further favor the concept of a protective effect of amlodipine. It will be interesting to see how many cases of crossover to an ACE inhibitor performed in patients who received the diuretic or the CCB were due to the presence of a diminished renal function and whether this could have contributed to create some biases in the final results. However, follow-ups longer than 5 yr are required to prove which is the most adequate antihypertensive therapy to maintain a preserved renal function.

CCB, BP Control, and Nephroprotection in Patients with Established Chronic Kidney Disease

According to recently published guidelines (16,17), the two main strategies to prevent progression of renal damage and to reduce cardiovascular risk in hypertensive patients with chronic kidney disease (CKD) are a strict BP control and the inhibition of the renin-angiotensin system. A strict BP control can be accompanied by reduction of proteinuria, but usually the fall in mean BP required to see a significant fall in proteinuria with practically any antihypertensive medication is >20 mmHg (18). However, recent data from the African American Study of Kidney Disease and Hypertension (AASK) study have shown that, in black patients, attained mean BP values of 128/78 mmHg did not differ from 141/85 mmHg in affording additional benefit of slowing the progressive fall in GFR values in hypertensive nephrosclerosis (12). This study suggests that in patients with nondiabetic renal disease, blockade of the renin-angiotensin system with either ACE inhibitor or ARB is superior to CCB in the progression of nephropathy in proteinuric patients. Amlodipine did seem to be equally effective as the ACE inhibitor when proteinuria was absent (12).

Data in proteinuric patients with type 2 diabetes obtained in the Irbesartan Diabetic Nephropathy Trial study (11) also showed that at equal BP levels, patients who received irbesartan showed a 20% risk reduction when compared with those who received placebo and a 23% risk reduction when compared with those who were treated with amlodipine. There was no difference between the amlodipine and placebo groups (11). The Reduction of Endpoints in Noninsulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan trial included a patient population similar to that investigated in Irbesartan Diabetic Nephropathy Trial, who were randomized to receive losartan or placebo. It is interesting that >80% of patients in both groups were treated adjunctively with CCB to achieve the goal of BP control (19). The positive effect of the ARB to halt the progression of renal failure was not jeopardized by the simultaneous administration of a CCB. Furthermore, the antiproteinuric effect of losartan was not abrogated by the presence of a CCB. Nondihydropiridine CCB have been shown to lead to a reduction in albuminuria or proteinuria, in particular when associated to an ACE inhibitor (20,21).

The data of the AASK (12) point to a positive effect on renal function of amlodipine in patients with nephrosclerosis without proteinuria. Such an effect must be attributed to the existence of a good BP control. However, here again, longer follow-ups are required to prove the capacities of an ACE inhibitor or an ARB to obtain more complete renal protection in these patients (22).

Conclusions

In hypertensive patients with or without CKD, CCB are excellent antihypertensive drugs. The presence of microalbuminuria or proteinuria forces the need to use an ACE inhibitor or an ARB but does not impede the consideration of a CCB as a part of the combination of agents that will be required by most, if not all, patients. In the absence of albuminuria and with a preserved GFR (>60 ml/min), a CCB can be contemplated as first-step therapy and seems to preserve GFR in an adequate manner. In the presence of a diminished GFR without albuminuria, a CCB can be used as first-step therapy. However, a high percentage of patients will require combination therapy, and the addition of an ACE inhibitor or an ARB will be adequate.

  • © 2005 American Society of Nephrology

References

  1. ↵
    National Institute of Diabetes and Digestive and Kidney Diseases: US Renal Data System: Annual Data Report. Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease, 1989
  2. ↵
    Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF: Renal function: The Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38 : 1782 –1787, 2001
    OpenUrlCrossRefPubMed
  3. ↵
    Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 : 2154 –2169, 2003
    OpenUrlFREE Full Text
  4. ↵
    Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140 : 167 –174, 2004
    OpenUrlCrossRefPubMed
  5. ↵
    Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R: Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis 42 : 617 –622, 2003
    OpenUrlCrossRefPubMed
  6. ↵
    Padwal R, Laupacis A: Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care 27 : 247 –255, 2004
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356 : 366 –372, 2000
    OpenUrlCrossRefPubMed
  8. ↵
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981 –2997, 2002
    OpenUrlCrossRefPubMed
  9. ↵
    Remuzzi G, Ruggenenti P, Perico N: Chronic renal disease: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136 : 604 –615, 2002
    OpenUrlCrossRefPubMed
  10. ↵
    Marin R, Ruilope LM, Aljama P, Aranda P, Segura J, Diez J: A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 19 : 1871 –1876, 2001
    OpenUrlCrossRefPubMed
  11. ↵
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 : 851 –860, 2001
    OpenUrlCrossRefPubMed
  12. ↵
    Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288 : 2421 –2431, 2002
    OpenUrlCrossRefPubMed
  13. ↵
    Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhager WH, de Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 19 : 511 –519, 2001
    OpenUrlCrossRefPubMed
  14. ↵
    Schier RW, Estacio R, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria retinopathy and strokes. Kidney Int 61 : 1086 –1097, 2002
    OpenUrlCrossRefPubMed
  15. ↵
    Romero JC, Ruilope LM, Bontley MD, Fiksen-Olsen MJ, Lahera V, Vidal MG: Comparison of the effects of calcium antagonist and converting enzyme inhibitor on renal function under normal and hypertensive conditions. Am J Cardiol 62 : 59G –68G, 1988
    OpenUrlPubMed
  16. ↵
    Chobanian A, Bakris GL, Black HR, Cushman W, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella E: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 : 2560 –2572, 2003
    OpenUrlCrossRefPubMed
  17. ↵
    Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 : 1011 –1053, 2003
    OpenUrlCrossRefPubMed
  18. ↵
    Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123 : 754 –762, 1995
    OpenUrlCrossRefPubMed
  19. ↵
    Brenner BM, Cooper MD, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861 –869, 2001
    OpenUrlCrossRefPubMed
  20. ↵
    Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54 : 1283 –1289, 1998
    OpenUrlCrossRefPubMed
  21. ↵
    The PROCOPA Study Group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: A randomised double-blind trial. J Hypertens 20 : 729 –737, 2002
    OpenUrlCrossRefPubMed
  22. ↵
    Segura J, Campo C, Rodicio JL, Ruilope LM: ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension 38 : 645 –649, 2001
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology
Vol. 16, Issue 3 suppl 1
1 Mar 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials
Julián Segura, José A. García-Donaire, Luis M. Ruilope
JASN Mar 2005, 16 (3 suppl 1) S64-S66; DOI: 10.1681/ASN.2004110969

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials
Julián Segura, José A. García-Donaire, Luis M. Ruilope
JASN Mar 2005, 16 (3 suppl 1) S64-S66; DOI: 10.1681/ASN.2004110969
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • CCB and Renal Protection in Recent Trials in Hypertensive Patients
    • CCB, BP Control, and Renal Protection in the Presence of Preserved Renal Function
    • CCB, BP Control, and Nephroprotection in Patients with Established Chronic Kidney Disease
    • Conclusions
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Impact of Target Organ Damage Assessment in the Evaluation of Global Risk in Patients with Essential Hypertension
  • Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation
  • Individual Titration for Maximal Blockade of the Renin-Angiotensin System in Proteinuric Patients: A Feasible Strategy?
Show more Articles

Cited By...

  • Effects of Calcium Channel Blockade on Angiotensin II-Induced Peritubular Ischemia in Rats
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire